📣 VC round data is live. Check it out!

PROCEPT BioRobotics Valuation Multiples

Discover revenue and EBITDA valuation multiples for PROCEPT BioRobotics and similar public comparables like Staar Surgical, Poly Medicure, Oxford Nanopore Technologies, Heron Neutron Medical and more.

PROCEPT BioRobotics Overview

About PROCEPT BioRobotics

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.


Founded

2021

HQ

United States

Employees

756

Financials (LTM)

Revenue: $343M
EBITDA: ($40M)

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

PROCEPT BioRobotics Financials

PROCEPT BioRobotics reported last 12-month revenue of $343M and negative EBITDA of ($40M).

In the same LTM period, PROCEPT BioRobotics generated $221M in gross profit, ($40M) in EBITDA losses, and had net loss of ($92M).

Revenue (LTM)


PROCEPT BioRobotics P&L

In the most recent fiscal year, PROCEPT BioRobotics reported revenue of $308M and EBITDA of ($50M).

PROCEPT BioRobotics is unprofitable as of last fiscal year, with gross margin of 64%, EBITDA margin of (16%), and net margin of (31%).

See analyst estimates for PROCEPT BioRobotics
LTMLast FY202320242025202620272028
Revenue$343M$308M$136M$224M$308M
Gross Profit$221M$196M$71M$137M$196M
Gross Margin64%64%52%61%64%
EBITDA($40M)($50M)($98M)($82M)($85M)
EBITDA Margin(12%)(16%)(72%)(37%)(28%)
EBIT Margin(29%)(34%)(80%)(43%)(34%)
Net Profit($92M)($96M)($106M)($91M)($96M)
Net Margin(27%)(31%)(78%)(41%)(31%)

Financial data powered by Morningstar, Inc.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics has current market cap of $2B, and enterprise value of $1B.

Market Cap Evolution


PROCEPT BioRobotics' stock price is $28.90.

PROCEPT BioRobotics share price increased by 20.2% in the last 30 days, and decreased by 50.2% in the last year.

PROCEPT BioRobotics has an EPS (earnings per share) of $-1.68.

See more trading valuation data for PROCEPT BioRobotics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$2B2.9%20.2%27.4%-50.2%$-1.68

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

PROCEPT BioRobotics Valuation Multiples

PROCEPT BioRobotics trades at 4.3x EV/Revenue multiple, and (36.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for PROCEPT BioRobotics

EV / Revenue (LTM)


PROCEPT BioRobotics Financial Valuation Multiples

As of May 22, 2026, PROCEPT BioRobotics has market cap of $2B and EV of $1B.

PROCEPT BioRobotics has a P/E ratio of (17.8x).

LTMLast FY202320242025202620272028
EV/Revenue4.3x4.8x10.8x6.6x4.8x
EV/EBITDA(36.5x)(29.4x)(15.1x)(18.0x)(17.3x)
EV/EBIT(14.9x)(14.2x)(13.5x)(15.3x)(14.2x)
EV/Gross Profit6.7x7.5x20.8x10.8x7.5x
P/E(17.8x)(17.2x)(15.5x)(18.0x)(17.2x)
EV/FCF(43.2x)(39.0x)(11.1x)(14.3x)(25.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified PROCEPT BioRobotics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

PROCEPT BioRobotics Margins & Growth Rates

PROCEPT BioRobotics grew revenue by 30% but EBITDA decreased by 50% in the last fiscal year.

In the most recent fiscal year, PROCEPT BioRobotics reported gross margin of 64%, EBITDA margin of (16%), and net margin of (31%).

See estimated margins and future growth rates for PROCEPT BioRobotics

PROCEPT BioRobotics Margins

Last FY202420252026202720282029
Gross Margin64%61%64%65%
EBITDA Margin(16%)(37%)(28%)(6%)
EBIT Margin(34%)(43%)(34%)(23%)
Net Margin(31%)(41%)(31%)(22%)
FCF Margin(12%)(46%)(19%)(7%)

PROCEPT BioRobotics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth30%65%37%30%
Gross Profit Growth33%93%43%33%
EBITDA Growth(50%)(16%)4%(71%)
EBIT Growth(11%)(12%)7%(11%)
Net Profit Growth(9%)(14%)5%(9%)
FCF Growth(25%)(22%)(44%)(51%)

Data powered by FactSet, Inc. and Morningstar, Inc.

PROCEPT BioRobotics Operational KPIs

PROCEPT BioRobotics' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.

PROCEPT BioRobotics' Rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PROCEPT BioRobotics' Rule of X is 67% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for PROCEPT BioRobotics
LTMLast FY202320242025202620272028
Rule of 4015%23%
Bessemer Rule of X55%67%
Revenue per Employee$0.4M
Opex per Employee$0.4M
R&D Expenses to Revenue22%23%36%28%23%
Opex to Revenue97%132%104%97%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

PROCEPT BioRobotics Competitors

PROCEPT BioRobotics competitors include Staar Surgical, Poly Medicure, Oxford Nanopore Technologies, Heron Neutron Medical, Qingdao Baheal Medical, Vitrolife, Cofoe Medical, Weigao Group, Haier Biomedical and Embla Medical.

Most PROCEPT BioRobotics public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Staar Surgical4.5x5.5x27.6x87.6x
Poly Medicure7.8x7.6x27.2x31.8x
Oxford Nanopore Technologies4.3x4.0x(11.2x)(12.9x)
Heron Neutron Medical3867.2x(90.4x)
Qingdao Baheal Medical1.7x1.6x13.4x13.4x
Vitrolife4.3x4.3x14.8x14.5x
Cofoe Medical2.7x2.5x14.4x13.7x
Weigao Group5.9x5.6x16.9x17.4x

This data is available for Pro users. Sign up to see all PROCEPT BioRobotics competitors and their valuation data.

Start Free Trial

PROCEPT BioRobotics Funding History

Before going public, PROCEPT BioRobotics raised $503M in total equity funding, across 6 rounds.

Last private valuation of PROCEPT BioRobotics was $873M, after raising $85M in June 2021 from CPMG, Duquesne Family Office, Fidelity, and 3 other investors.


PROCEPT BioRobotics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Oct-24Secondary - public$175M
Jun-21Series GCPMG; Duquesne Family Office; Fidelity; Perceptive Advisors; T. Rowe Price; Viking Global Investors$85M$873MPROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company focused on urology, developing and selling the AquaBeam Robotic System for minimally invasive treatment of benign prostatic hyperplasia (BPH) via Aquablation therapy, which provides image-guided, predictable outcomes independent of prostate size or surgeon experience. On June 30, 2021, the company closed an $85 million Series G financing round led by Fidelity Management & Research Company LLC, with participation from new investor T. Rowe Price Associates and existing investors CPMG, Perceptive Advisors, Viking Global Investors, and Duquesne Family Office. Proceeds were intended to support global commercial expansion of the AquaBeam system. The post-money valuation for the Series G round was $872.62 million, based on company-submitted Certificate of Incorporation. Total funding raised by PROCEPT BioRobotics to date stood at $341.8 million. The company had achieved key clinical validations and favorable coverage from Medicare and large commercial payors like Anthem, BlueCross Massachusetts, Emblem Health, Health Care Service Corp, and Humana, positioning it for broader market adoption in a U.S. addressable market of approximately 8.2 million BPH patients. Financially, PROCEPT reported revenue of $15.7 million for the six months ended June 30, 2021, up from $2.4 million in the prior-year period, alongside a net loss of $27.4 million. For the full year 2020, revenue was $7.7 million with a net loss of $53.0 million. As of June 30, 2021, accumulated deficit reached $229.1 million.
Aug-20Series F$77M$530MPROCEPT BioRobotics is a surgical robotics company developing intelligent solutions for urology, specifically the AquaBeam Robotic System, an advanced image-guided surgical system that delivers Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH). The system offers predictable and reproducible outcomes independent of prostate anatomy, size, or surgeon experience, addressing a large patient population—approximately 40 million men in the United States are impacted by BPH, making it the number one reason men visit a urologist. In August 2020, PROCEPT completed a Series F financing round of $77.52 million at a post-money valuation of $529.89 million, led by multiple investors participating in the round. For the year ended December 31, 2020, the company generated revenue of $7.7 million while incurring a net loss of $53.0 million, demonstrating early commercialization of the Aquablation platform. The company had secured favorable coverage decisions from several major commercial payors including Anthem, BlueCross Massachusetts, Emblem Health, Health Care Service Corp, and Humana, positioning it for expanded market penetration. PROCEPT subsequently completed a Series G financing round of $85 million in June 2021 and went public via IPO on September 15, 2021.
Feb-18Series ECPMG; Perceptive Advisors; Viking Global Investors$118MPROCEPT BioRobotics, a Silicon Valley-based surgical robotics company, raised $118 million in an equity financing round announced around February 22 to March 19, 2018, led by Viking Global Investors with participation from new investor Perceptive Advisors and existing investor CPMG. The funds were earmarked for the worldwide commercialization of its Aquablation therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH) using the FDA-approved Aquabeam System, which employs high-pressure water jet technology combined with real-time imaging and robotics for precise, heat-free prostate tissue removal. The Aquabeam System received de novo FDA clearance in December 2017 and was commercially available in the US, Canada, Australia, New Zealand, and select European markets at the time of the round. CEO Nikolai Aljuri emphasized that investors shared the vision to establish Aquablation as the standard BPH treatment, citing its potential to improve patient outcomes without common sexual side effects of traditional therapies. CPMG partner Antal Desai highlighted the innovation and clinical results from the double-blind randomized WATER study supporting its paradigm-shifting potential. Prior to this round, PROCEPT had raised $6 million in equity and $1.6 million in debt in 2013-2014, followed by a $42 million round led by Novo in 2015 with CPMG. The company focused on urology solutions, positioning Aquablation as a transformative alternative backed by impressive clinical data.
Jul-15Series DCPMG; Novo Holdings$42MPROCEPT BioRobotics, a Silicon Valley-based medical device company, closed a $42 million venture equity financing round on July 7, 2015, led by Novo A/S with participation from new investor CPMG, Inc. and existing investors. The company develops Aquablation, a technology aimed at treating benign prostatic hyperplasia (BPH), with promising clinical data suggesting potential to become a new standard of care. Novo A/S, part of the Novo Nordisk Foundation, focuses on venture capital in life sciences and biotechnology, while CPMG employs a value-oriented investment approach in private companies. The round supports PROCEPT's ongoing development, including a pivotal trial for Aquablation to address unmet needs in BPH treatment affecting millions of patients.
Oct-13Series C$6MPROCEPT BioRobotics raised $6.05 million in its Series A funding round in October 2013. The company, headquartered in Redwood Shores, California, develops the AquaBeam Robotic System, an image-guided surgical platform for minimally invasive treatment of benign prostatic hyperplasia (BPH). The company later went public on Nasdaq in 2021, raising $163.9 million in gross proceeds, and by 2025 had achieved approximately $325.5 million in annual revenue with 43% year-over-year growth.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About PROCEPT BioRobotics

When was PROCEPT BioRobotics founded?PROCEPT BioRobotics was founded in 2021.
Where is PROCEPT BioRobotics headquartered?PROCEPT BioRobotics is headquartered in United States.
How many employees does PROCEPT BioRobotics have?As of today, PROCEPT BioRobotics has over 756 employees.
Who is the CEO of PROCEPT BioRobotics?PROCEPT BioRobotics' CEO is Larry L. Wood.
Is PROCEPT BioRobotics publicly listed?Yes, PROCEPT BioRobotics is a public company listed on Nasdaq.
What is the stock symbol of PROCEPT BioRobotics?PROCEPT BioRobotics trades under PRCT ticker.
When did PROCEPT BioRobotics go public?PROCEPT BioRobotics went public in 2021.
Who are competitors of PROCEPT BioRobotics?PROCEPT BioRobotics main competitors include Staar Surgical, Poly Medicure, Oxford Nanopore Technologies, Heron Neutron Medical, Qingdao Baheal Medical, Vitrolife, Cofoe Medical, Weigao Group, Haier Biomedical, Embla Medical.
What is the current market cap of PROCEPT BioRobotics?PROCEPT BioRobotics' current market cap is $2B.
What is the current revenue of PROCEPT BioRobotics?PROCEPT BioRobotics' last 12 months revenue is $343M.
What is the current revenue growth of PROCEPT BioRobotics?PROCEPT BioRobotics revenue growth (NTM/LTM) is 27%.
What is the current EV/Revenue multiple of PROCEPT BioRobotics?Current revenue multiple of PROCEPT BioRobotics is 4.3x.
Is PROCEPT BioRobotics profitable?No, PROCEPT BioRobotics is not profitable.
What is the current EBITDA of PROCEPT BioRobotics?PROCEPT BioRobotics has negative EBITDA and is not profitable.
What is PROCEPT BioRobotics' EBITDA margin?PROCEPT BioRobotics' last 12 months EBITDA margin is (12%).
What is the current EV/EBITDA multiple of PROCEPT BioRobotics?Current EBITDA multiple of PROCEPT BioRobotics is (36.5x).
What is the current FCF of PROCEPT BioRobotics?PROCEPT BioRobotics' last 12 months FCF is ($34M).
What is PROCEPT BioRobotics' FCF margin?PROCEPT BioRobotics' last 12 months FCF margin is (10%).
What is the current EV/FCF multiple of PROCEPT BioRobotics?Current FCF multiple of PROCEPT BioRobotics is (43.2x).
How many companies PROCEPT BioRobotics has acquired to date?PROCEPT BioRobotics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies PROCEPT BioRobotics has invested to date?PROCEPT BioRobotics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to PROCEPT BioRobotics

Lists including PROCEPT BioRobotics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial